These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17483670)

  • 1. Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly.
    Hanes DS; Weir MR
    Am J Geriatr Cardiol; 2007; 16(3):175-82. PubMed ID: 17483670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors.
    Fournier A; Oprisiu-Fournier R; Serot JM; Godefroy O; Achard JM; Faure S; Mazouz H; Temmar M; Albu A; Bordet R; Hanon O; Gueyffier F; Wang J; Black S; Sato N
    Expert Rev Neurother; 2009 Sep; 9(9):1413-31. PubMed ID: 19769454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of dementia: lessons from SYST-EUR and PROGRESS.
    Hanon O; Forette F
    J Neurol Sci; 2004 Nov; 226(1-2):71-4. PubMed ID: 15537524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the renin-angiotensin system and the prevention of stroke.
    Schrader J; Kulschewski A; Dendorfer A
    Am J Cardiovasc Drugs; 2007; 7(1):25-37. PubMed ID: 17355164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment.
    Poon IO
    Pharmacotherapy; 2008 Mar; 28(3):366-75. PubMed ID: 18294116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?
    Messerli FH; Bangalore S; Bavishi C; Rimoldi SF
    J Am Coll Cardiol; 2018 Apr; 71(13):1474-1482. PubMed ID: 29598869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD008117. PubMed ID: 24488616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinical usefulness of RAAS inhibitors in hypertensive patients].
    Yamaguchi K; Sata M
    Nihon Rinsho; 2012 Sep; 70(9):1571-6. PubMed ID: 23012805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cerebrovascular sequelae of hypertension].
    Schrader J; Lüders S; Diener HC
    Herz; 2003 Dec; 28(8):707-16. PubMed ID: 14689105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme?
    de Gasparo M; Levens N
    Pharmacol Toxicol; 1998 Jun; 82(6):257-71. PubMed ID: 9677617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine.
    Ball SG; White WB
    Am J Cardiol; 2003 May; 91(10A):15G-21G. PubMed ID: 12781904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin receptor blockers: evidence for preserving target organs.
    Carson P; Giles T; Higginbotham M; Hollenberg N; Kannel W; Siragy HM
    Clin Cardiol; 2001 Mar; 24(3):183-90. PubMed ID: 11288962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive Medication Class and the Risk of Dementia and Cognitive Decline in Older Adults: A Secondary Analysis of the Prospective HELIAD Cohort.
    Liampas I; Hatzimanolis A; Siokas V; Yannakoulia M; Kosmidis MH; Sakka P; Hadjigeorgiou GM; Scarmeas N; Dardiotis E
    J Alzheimers Dis; 2022; 89(2):709-719. PubMed ID: 35912747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of different antihypertensive medication groups on cognitive function in older patients: A systematic review.
    Stuhec M; Keuschler J; Serra-Mestres J; Isetta M
    Eur Psychiatry; 2017 Oct; 46():1-15. PubMed ID: 28992530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
    Ferrari R; Boersma E
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.